Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia

Chinese Medical Sciences Journal

Volumn 19, Issue 2, 2004, Pages 145-149

  Hong, Heng ^a   Xu, Zhi Min ^a   Pang, Bao Sen ^b   Cui, Liang ^a   Wei, Yu ^a   Guo, Wen Jing ^b   Mao, Yan Ling ^b   Yang, Xin Chun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Respiratory Medicine   (China)

Author keywords

High sensitive C reactive protein; Mixed dyslipidemia; Omega 3 fatty acids; Simvastation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEILEKANG; OMEGA 3 FATTY ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FIBRINOLYSIS; HUMANS; LIPIDS; MALE; MIDDLE AGED; SIMVASTATIN; TRIGLYCERIDES;

EID: 3142626358     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lu ZL, Xu ZM. The treatment of dyslipidemia. Beijing: People Health Publishing House. 2002.p.50-117.
2. Nordoy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998;243:163-70.
3. Durrington PN, Bhatnagar D, Morgan J, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8.
4. Nordoy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 2003;1:690-7
5. Ridker PM, Glynn RJ, Hennekens CH, et al. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of fist myocardial infarction. Circulation 1998;97:2007-11.
6. Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract 2003;57:305-14
7. Madsen T, Skou HA, Hansen VE, et al. C-reactive protein, dietary n-3 fatty acid, and the extent of coronary artery disease. Am J Cardiol 2001;88:1139-42.
8. Cleeman JI. Executive summary of the thrid report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (adult treatment panel III). JAMA 2001;285:2486-97.
9. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
10. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
11. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rtheumatoid arthritis. Semin Arthritis Rheum 1997;27:85-97.
12. Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 1999;2:117-20.